- Home
- MSTR vs ZTS Comparison
MSTR vs ZTS Comparison
Compare MSTR & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSTR | ZTS |
|---|---|---|
| Founded | 1989 | 1952 |
| Country | United States | United States |
| Employees | N/A | 14500 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4B | 48.7B |
| IPO Year | 1998 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MSTR | ZTS |
|---|---|---|
| Price | $140.19 | $115.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $354.15 | $156.20 |
| AVG Volume (30 Days) | ★ 14.9M | 3.7M |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 1.84% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 6.02 |
| Revenue | $463,456,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | $4.71 | $5.69 |
| Revenue Next Year | $0.32 | $4.81 |
| P/E Ratio | ★ N/A | $19.16 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $105.00 | $115.25 |
| 52 Week High | $457.22 | $172.23 |
Technical Indicators
Market Signals| Indicator | MSTR | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 30.78 |
| Support Level | $118.40 | N/A |
| Resistance Level | $149.54 | $130.52 |
| Average True Range (ATR) | 7.04 | 3.17 |
| MACD | 1.65 | -1.35 |
| Stochastic Oscillator | 69.24 | 7.77 |
Price Performance
Historical ComparisonAbout MSTR MicroStrategy Incorporated
Strategy Inc is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provides industry AI-powered enterprise analytics software.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.